Blaze Bioscience Inc. Ropes in $8.1 Million for Tumor Targeting “Paint”

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Seattle-based startup Blaze Biosciences raises $8.1M in Series B funding for its tumor-targeting “paint” technology. healthcare funding

Blaze Biosciences is more than halfway to a targeted $15 million in a Series B round to fund its Tumor Paint, a surgical tool that visually distinguishes solid tumor cells from healthy cells.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC